https://orcid.org/0000-0002-8401-1481
Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Ravi K Goyal, Jingchuan Zhang, Keith L Davis, Martina Sluga-O’Callaghan & Peter A Kaufman. (2023) Early Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin After Prior Immuno-Oncology or Antibody–Drug Conjugate Therapy. Breast Cancer: Targets and Therapy 15, pages 855-865.
Read now
Read now
Zhiqiang Yang & Fan He. (2023) An immune cell infiltration landscape classification to predict prognosis and immunotherapy effect in oral squamous cell carcinoma. Computer Methods in Biomechanics and Biomedical Engineering 0:0, pages 1-13.
Read now
Read now
Ai-Yan Xing, Long Liu, Ke Liang & Bin Wang. (2022) p53 Missense Mutation is Associated with Immune Cell PD-L1 Expression in Triple-Negative Breast Cancer. Cancer Investigation 40:10, pages 879-888.
Read now
Read now
Alessandro Rizzo, Angela Dalia Ricci, Laura Lanotte, Lucia Lombardi, Alessandro Di Federico, Giovanni Brandi & Gennaro Gadaleta-Caldarola. (2022) Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects. Expert Opinion on Investigational Drugs 31:6, pages 557-565.
Read now
Read now
Alessandro Rizzo & Angela Dalia Ricci. (2022) Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opinion on Investigational Drugs 31:6, pages 549-555.
Read now
Read now
Mingming Yin, Jinlong Hu, Zhongxu Yuan, Guangyi Luo, Jiaming Yao, Rundong Wang, Dongquan Liu, Baoqiang Cao, Wenyong Wu & Zhiqi Hu. (2022) STING agonist enhances the efficacy of programmed death-ligand 1 monoclonal antibody in breast cancer immunotherapy by activating the interferon-β signalling pathway. Cell Cycle 21:8, pages 767-779.
Read now
Read now
Chen Yuan, Jie Zhang, Jianjuan Lou, Siqi Wang, Yanni Jiang, Feiyun Wu & Shouju Wang. (2021) Comprehensive Analysis of Monocarboxylate Transporter 4 (MCT4) expression in breast cancer prognosis and immune infiltration via integrated bioinformatics analysis. Bioengineered 12:1, pages 3850-3863.
Read now
Read now
Articles from other publishers (34)
Jinghan Yang, Liang Qiu, Xi Wang, Xi Chen, Pingdong Cao, Zhe Yang & Qiang Wen. (2023) Liquid biopsy biomarkers to guide immunotherapy in breast cancer. Frontiers in Immunology 14.
Crossref
Crossref
Yazhen Wang, Yang Zhou, Lianyi Yang, Lei Lei, Bin He, Jun Cao & Huile Gao. (2023) Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD‐L1 in Cancer Therapy. Advanced Science.
Crossref
Crossref
Lianjie Wang, Hui Geng, Yujie Liu, Lei Liu, Yanhua Chen, Fanchen Wu, Zhiyi Liu, Shiliang Ling, Yan Wang & Lihong Zhou. (2023) Hot and cold tumors: Immunological features and the therapeutic strategies. MedComm 4:5.
Crossref
Crossref
Sudip Kumar Mandal, Agnidipta Das, Anindya Bose, Vagish Dwibedi, Paramita Ganguly, Sipra Sarkar, Ranjana Prakash, Biplab Kumar Dey, Sanjeet Mandal & Santosh Kumar Rath. (2023) Hetero Cyclic Compounds in the Treatment of Triple-Negative Breast
Cancer. Current Cancer Therapy Reviews 19:3, pages 237-259.
Crossref
Crossref
Noha A. Selem, Heba Nafae, Tamer Manie, Rana A. Youness & Mohamed Z. Gad. (2023) Let-7a/cMyc/CCAT1/miR-17–5p Circuit Re-sensitizes Atezolizumab Resistance in Triple Negative Breast Cancer through Modulating PD-L1. Pathology - Research and Practice 248, pages 154579.
Crossref
Crossref
Uttpal Anand, Abhijit Dey, Arvind K. Singh Chandel, Rupa Sanyal, Amarnath Mishra, Devendra Kumar Pandey, Valentina De Falco, Arun Upadhyay, Ramesh Kandimalla, Anupama Chaudhary, Jaspreet Kaur Dhanjal, Saikat Dewanjee, Jayalakshmi Vallamkondu & José M. Pérez de la Lastra. (2023) Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes & Diseases 10:4, pages 1367-1401.
Crossref
Crossref
Shanshan Liu, Ziwei Ye, Vivian Weiwen Xue, Qi Sun, Huan Li & Desheng Lu. (2023) KIF2C is a prognostic biomarker associated with immune cell infiltration in breast cancer. BMC Cancer 23:1.
Crossref
Crossref
Tingting Yang, Lihua Kang, Dan Li & Yanqiu Song. (2023) Immunotherapy for HER-2 positive breast cancer. Frontiers in Oncology 13.
Crossref
Crossref
Hsiu-Chuan Wei. (2023) Mathematical modeling of tumor growth and treatment: Triple negative breast cancer. Mathematics and Computers in Simulation 204, pages 645-659.
Crossref
Crossref
Varduhi Petrosyan, Lacey E. Dobrolecki, Lillian Thistlethwaite, Alaina N. Lewis, Christina Sallas, Ramakrishnan R. Srinivasan, Jonathan T. Lei, Vladimir Kovacevic, Predrag Obradovic, Matthew J. Ellis, C. Kent Osborne, Mothaffar F. Rimawi, Anne Pavlick, Maryam Nemati Shafaee, Heidi Dowst, Antrix Jain, Alexander B. Saltzman, Anna Malovannaya, Elisabetta Marangoni, Alana L. Welm, Bryan E. Welm, Shunqiang Li, Gerburg M. Wulf, Olmo Sonzogni, Chen Huang, Suhas Vasaikar, Susan G. Hilsenbeck, Bing Zhang, Aleksandar Milosavljevic & Michael T. Lewis. (2023) Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach. iScience 26:1, pages 105799.
Crossref
Crossref
Mohamed El-Tanani, Arwa Omar Al Khatib, Belal O. Al-Najjar, Ashok K. Shakya, Yahia El-Tanani, Yin-Fai Lee, Ángel Serrano-Aroca, Vijay Mishra, Yachana Mishra, Alaa A. Aljabali, Rohit Goyal, Poonam Negi, Marzieh Ramezani Farani, Maryam Moradi Binabaj, Amir Gholami, Nitin B. Charbe & Murtaza M. Tambuwala. (2023) Cellular and molecular basis of therapeutic approaches to breast cancer. Cellular Signalling 101, pages 110492.
Crossref
Crossref
Melisa B. Nicoud, Mónica A. Táquez Delgado, Ignacio Ospital, Helena A. Sterle, Karina Formoso & Vanina A. Medina. 2023.
Ruoning Yang, Yueyi Li, Hang Wang, Taolin Qin, Xiaomeng Yin & Xuelei Ma. (2022) Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy. Molecular Biomedicine 3:1.
Crossref
Crossref
Chen Yuan, Yang Li, Ziqing Xu, Chuanbing Wang, Jie Zhang, Yingying Jin, Zhihui Chen, Hanyao Sun, Feiyun Wu, Qingling Zhang, Yuxia Tang & Shouju Wang. (2022) Imaging-Guided Synergistic Photo-Chemotherapy Using Doxorubicin-Loaded Gadolinium Porphyrin-Based Metal–Organic Framework Nanosheets. ACS Applied Nano Materials 5:10, pages 15318-15327.
Crossref
Crossref
Hossein Taghizadeh & Gerald W. Prager. (2022) Immune Checkpoint Inhibitors for Advanced Biliary Tract Cancer. Current Cancer Drug Targets 22:8, pages 639-650.
Crossref
Crossref
Tingting Liang, Lu Lu, Xueting Song, Jianguo Qi & Jianhong Wang. (2022) Combination of microtubule targeting agents with other antineoplastics for cancer treatment. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877:5, pages 188777.
Crossref
Crossref
Ming Yang, Olamide Tosin Olaoba, Chunye Zhang, Eric T. Kimchi, Kevin F. Staveley-O’Carroll & Guangfu Li. (2022) Cancer Immunotherapy and Delivery System: An Update. Pharmaceutics 14:8, pages 1630.
Crossref
Crossref
Li Chen, Tianjian Chen, Ya Zhang, Haichen Lin, Ruihan Wang, Yihang Wang, Hongyu Li, Zhixiang Zuo, Jian Ren & Yubin Xie. (2022) TIRSF: a web server for screening gene signatures to predict Tumor immunotherapy response. Nucleic Acids Research 50:W1, pages W761-W767.
Crossref
Crossref
Alessandro Rizzo, Antonio Cusmai, Raffaella Massafra, Samantha Bove, Maria Colomba Comes, Annarita Fanizzi, Lucia Rinaldi, Silvana Acquafredda, Gennaro Gadaleta-Caldarola, Donato Oreste, Alfredo Zito, Francesco Giotta, Vito Lorusso & Gennaro Palmiotti. (2022) Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis. Cells 11:12, pages 1857.
Crossref
Crossref
Yufei Ma, Weidong Li, Kai Ma, Tianyun Wang & Huigen Feng. (2022) Cell Surface Markers and their Targeted Drugs in Breast Cancer. Current Protein & Peptide Science 23:5, pages 335-346.
Crossref
Crossref
Ying-Zi Li, Bo Chen, Xiao-Yi Lin, Guo-Chun Zhang, Jian-Guo Lai, Cheukfai Li, Jia-Li Lin, Li-Ping Guo, Wei-Kai Xiao, Hsiaopei Mok, Chong-Yang Ren, Ling-Zhu Wen, Fang-Rong Cao, Xin Lin, Xiao-Fang Qi, Yang Liu & Ning Liao. (2022) Clinicopathologic and Genomic Features in Triple-Negative Breast Cancer Between Special and No-Special Morphologic Pattern. Frontiers in Oncology 12.
Crossref
Crossref
Aaron Kaplan, Min Jun Li & Rachna Malani. (2022) Treatments on the Horizon: Breast Cancer Patients with Central Nervous System Metastases. Current Oncology Reports 24:3, pages 343-350.
Crossref
Crossref
Harishini Rajaratinam, Noor Fatmawati Mokhtar, Nurul Asma-Abdullah & Wan Ezumi Mohd Fuad. (2022) Discovering the Triad between Nav1.5, Breast Cancer, and the Immune System: A Fundamental Review and Future Perspectives. Biomolecules 12:2, pages 310.
Crossref
Crossref
Louay S Abdulkarim & Richard J Motley. (2021) First-line Advanced Cutaneous Melanoma Treatments: Where Do We Stand?. JMIR Cancer 7:4, pages e29912.
Crossref
Crossref
Liting Xue, Xingyuan Gao, Haoyu Zhang, Jianxing Tang, Qian Wang, Feng Li, Xinxin Li, Xiaohong Yu, Zhihong Lu, Yue Huang, Renhong Tang & Wenqing Yang. (2021) Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment. BMC Cancer 21:1.
Crossref
Crossref
Elham Masoumi, Sahar Tahaghoghi-Hajghorbani, Leila Jafarzadeh, Mohammad-Javad Sanaei, Atieh Pourbagheri-Sigaroodi & Davood Bashash. (2021) The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle. Journal of Controlled Release 340, pages 168-187.
Crossref
Crossref
Chen Mei, Liang Xin, Yang Liu, Jiabao Lin, Hong Xian, Xue Zhang, Wei Hu, Zhaofei Xia, Hongjun Wang & Yanli Lyu. (2021) Establishment of a New Cell Line of Canine Mammary Tumor CMT-1026. Frontiers in Veterinary Science 8.
Crossref
Crossref
Coral García-Fernández, Anna Saz, Cristina Fornaguera & Salvador Borrós. (2021) Cancer immunotherapies revisited: state of the art of conventional treatments and next-generation nanomedicines. Cancer Gene Therapy 28:9, pages 935-946.
Crossref
Crossref
Fatma Al-Mulhim, Amany I. Alqosaibi, Afnan Al-Muhnna, Khalid Farid, Shaimaa Abdel-Ghany, Hamdy Rizk, Abdel-Bary Prince, Adaugo Isichei & Hussein Sabit. (2021) CRISPR/Cas9-mediated activation of CDH1 suppresses metastasis of breast cancer in rats. Electronic Journal of Biotechnology 53, pages 54-60.
Crossref
Crossref
Jacopo Giuliani, Beatrice Mantoan & Andrea Bonetti. (2021) The cost-effectiveness of atezolizumab in first-line for metastatic triple negative breast cancer is heavily linked to PD-L1 level. Journal of Oncology Pharmacy Practice 27:5, pages 1245-1247.
Crossref
Crossref
Yuanyuan Wang, Tingxuan Gu, Xueli Tian, Wenwen Li, Ran Zhao, Wenqian Yang, Quanli Gao, Tiepeng Li, Jung-Hyun Shim, Chengjuan Zhang, Kangdong Liu & Mee-Hyun Lee. (2021) A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy. Frontiers in Immunology 12.
Crossref
Crossref
Rik Derynck, Shannon J. Turley & Rosemary J. Akhurst. (2020) TGFβ biology in cancer progression and immunotherapy. Nature Reviews Clinical Oncology 18:1, pages 9-34.
Crossref
Crossref
Jay V. Shah, Amber Gonda, Rahul Pemmaraju, Aishwarya Subash, Carolina Bobadilla Mendez, Marissa Berger, Xinyu Zhao, Shuqing He, Richard E. Riman, Mei Chee Tan, Mark C. Pierce, Prabhas V. Moghe & Vidya Ganapathy. (2020) Shortwave Infrared-Emitting Theranostics for Breast Cancer Therapy Response Monitoring. Frontiers in Molecular Biosciences 7.
Crossref
Crossref
Mohamed A. Alfaleh, Hashem O. Alsaab, Ahmad Bakur Mahmoud, Almohanad A. Alkayyal, Martina L. Jones, Stephen M. Mahler & Anwar M. Hashem. (2020) Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. Frontiers in Immunology 11.
Crossref
Crossref